ContraFect
Yonkers
About ContraFect
ContraFect is a biotechnology company pioneering the use of monoclonal antibodies to treat life-threatening infectious diseases. It addresses multi-drug resistant infections using therapeutic products from its lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. Its novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills bacteria. The company was founded in 2008 and is headquartered in Yonkers, New York.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $330.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2022)
- Ticker: nasdaq:CFRXU
- Website: contrafect.com
- Phone: 9142072300
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/contrafect-142367 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.